Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: The international telaprevir access program

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10285017" target="_blank" >RIV/00216208:11110/14:10285017 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.jhep.2014.06.005" target="_blank" >http://dx.doi.org/10.1016/j.jhep.2014.06.005</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jhep.2014.06.005" target="_blank" >10.1016/j.jhep.2014.06.005</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: The international telaprevir access program

Popis výsledku v původním jazyce

Background & Aims: There is little information regarding the extent to which difficult to cure patients with advanced liver fibrosis, due to hepatitis C virus genotype-1 (HCV-1) can successfully and safely be treated with triple therapy with telaprevir (TVR), pegylated interferon alpha (P) and ribavirin (R). In the TVR early access program HEP3002 we aimed to explore treatment safety and efficacy, and identify predictors of sustained virological response at week 24 (SVR24). Methods: 1078 patients with bridging fibrosis (n = 552) or cirrhosis (n = 526) diagnosed by either liver biopsy or non-invasive markers, with compensated bone marrow (neutrophils >1500/mm(3), Hb >12/13 g/dl) and liver function (Albumin >3.3 g/dl, Platelets >90,000/ml) received TVR PR for 12 weeks, followed by a PR tail according to label. Results: Overall, 614 (57%) achieved SVR24 by intention-to-treat analysis. The SVR24 rate was 68% in 221 treatment naive patients (62.8% F4), 72% in 356 prior relapsers (64.4% F4),

Název v anglickém jazyce

Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: The international telaprevir access program

Popis výsledku anglicky

Background & Aims: There is little information regarding the extent to which difficult to cure patients with advanced liver fibrosis, due to hepatitis C virus genotype-1 (HCV-1) can successfully and safely be treated with triple therapy with telaprevir (TVR), pegylated interferon alpha (P) and ribavirin (R). In the TVR early access program HEP3002 we aimed to explore treatment safety and efficacy, and identify predictors of sustained virological response at week 24 (SVR24). Methods: 1078 patients with bridging fibrosis (n = 552) or cirrhosis (n = 526) diagnosed by either liver biopsy or non-invasive markers, with compensated bone marrow (neutrophils >1500/mm(3), Hb >12/13 g/dl) and liver function (Albumin >3.3 g/dl, Platelets >90,000/ml) received TVR PR for 12 weeks, followed by a PR tail according to label. Results: Overall, 614 (57%) achieved SVR24 by intention-to-treat analysis. The SVR24 rate was 68% in 221 treatment naive patients (62.8% F4), 72% in 356 prior relapsers (64.4% F4),

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Hepatology

ISSN

0168-8278

e-ISSN

—

Svazek periodika

61

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

8

Strana od-do

976-983

Kód UT WoS článku

000343839900004

EID výsledku v databázi Scopus

—